These Numbers Reveal How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is

The trading price of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) closed lower on Tuesday, April 02, closing at $27.98, -6.76% lower than its previous close.

In examining the 52-week price action we see that the stock hit a 52-week high of $36.25 and a 52-week low of $9.44. Over the past month, the stock has lost -4.73% in value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

4D Molecular Therapeutics Inc, whose market valuation is $1.39 billion at the time of this writing, is expected to release its quarterly earnings report May 08, 2024 – May 13, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.72 per share this quarter, however they have predicted annual earnings per share of -$3.07 for 2024 and -$3.4 for 2025. It means analysts are expecting annual earnings per share growth of -19.00% this year and -10.70% next year.

The average estimate suggests sales will likely up by 161.70% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $5.76 million. The company’s revenue is forecast to drop by -72.20% over what it did in 2024.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of 4D Molecular Therapeutics Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest FDMT has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

A quick review shows that FDMT’s price is currently -9.72% off the SMA20 and 3.21% off the SMA50. The RSI metric on the 14-day chart is currently showing 43.18, and weekly volatility stands at 8.73%. When measured over the past 30 days, the indicator reaches 6.65%. 4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s beta value is currently sitting at 2.87, while the Average True Range indicator is currently displaying 2.18.

To see how 4D Molecular Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: FDMT stock’s performance was -6.76% in the latest trading, and 67.04% in the past year.

An evaluation of the daily trading volume of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) indicates that the 3-month average is 1.17 million. However, this figure has increased over the past 10 days to an average of 0.74 million.

Currently, records show that 49.78 million of the company’s shares remain outstanding. The insiders hold 12.43% of outstanding shares, whereas institutions hold 74.91%. The stats also highlight that short interest as of Mar 15, 2024, stood at 8.5 million shares, resulting in a short ratio of 10.54 at that time. From this, we can conclude that short interest is 17.08% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 7.06 million. However, since the stock’s price has seen 38.10% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.